In
Eli Lilly & Company v. Hospira, Inc., Nos. 2018-2128,
2018-2127 (Fed. Cir. Aug. 9, 2019), the Federal Circuit
affirmed the district court's application of the doctrine of
equivalents and clarified that the tangential exception of
prosecution history estoppel should not be viewed too
rigidly.
The dispute centered on whether Lilly's claims at issue,
which recited particular methods of treatment by administering
pemetrexed disodium, covered administration of a different
pemetrexed salt, pemetrexed ditromethamine, under DOE. During
patent prosecution, Lilly submitted a claim amendment changing
"an antifolate" to "pemetrexed disodium." The
Federal Circuit held that the amendment did not bar the application
of DOE because narrowing "antifolate" to "pemetrexed
disodium" could not possibly distinguish art referencing
pemetrexed disodium in then-pending obviousness rejections. The
court emphasized that when determining whether prosecution history
estoppel applies to